LY2784544
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Myeloproliferative Neoplasms of
Conditions
Myeloproliferative Neoplasms of, Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis
Trial Timeline
Jun 11, 2012 → Feb 24, 2017
NCT ID
NCT01520220About LY2784544
LY2784544 is a phase 1 stage product being developed by Eli Lilly for Myeloproliferative Neoplasms of. The current trial status is completed. This product is registered under clinical trial identifier NCT01520220. Target conditions include Myeloproliferative Neoplasms of, Polycythemia Vera, Essential Thrombocythemia.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01520220 | Phase 1 | Completed |
| NCT01134120 | Phase 1 | Completed |
Competing Products
20 competing products in Myeloproliferative Neoplasms of